

**Postneo/adjuvante Studien im
Netzwerk Mamma WestGoBreast**
Optimierung der Therapie- Optimierung des
Überlebens

Astefania Studie: HER2 pos. postneoadjuvant

Patients with HER2-positive EBC and:

- Residual invasive disease in the breast and/or axillary lymph nodes at surgery following preoperative therapy (chemotherapy and HER2-directed therapy)
- Centrally confirmed HER2-positive, and hormone receptor and PD-L1 status[†]

n = 1700

Stratification factors: clinical stage, hormone receptor status, preoperative HER2-directed therapy, PD-L1 status

[†]PD-L1 status access using SP142

Randomization

T-DM1
+
atezolizumab
(14 cycles)


T-DM1
+
placebo
(14 cycles)

Follow-up
(up to
10 years
post-LPI)

HR pos. adjuvant




ADAPTlate – Studiendesign




HR pos. und TNBC postneoadjuvant

SASCIA: postneoadjuvante Therapie mit Sacituzumab Govitecan in TNBC und HR pos. eBC



HER 2 pos. postneoadjuvant



- Randomisierung < 12 Wochen nach Brust-OP
- Adjuvante Radiotherapie und/oder endokrine Therapie per Protokoll und lokalen Richtlinien

Strata:

- Operabel versus Inoperabel
- Nodalstatus nach NACT (positiv versus negativ)
- Hormonrezeptorstatus (positiv versus negativ)
- NACT (einfache Blockade versus doppelte Blockade)